CA3030149A1 - Prevention and treatment of atrial fibrillation/flutter with gamma-ketoaldehyde scavengers - Google Patents

Prevention and treatment of atrial fibrillation/flutter with gamma-ketoaldehyde scavengers Download PDF

Info

Publication number
CA3030149A1
CA3030149A1 CA3030149A CA3030149A CA3030149A1 CA 3030149 A1 CA3030149 A1 CA 3030149A1 CA 3030149 A CA3030149 A CA 3030149A CA 3030149 A CA3030149 A CA 3030149A CA 3030149 A1 CA3030149 A1 CA 3030149A1
Authority
CA
Canada
Prior art keywords
optionally substituted
membered ring
ring containing
compound
atrial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3030149A
Other languages
English (en)
French (fr)
Inventor
Katherine T. MURRAY
L. Jackson Ii Roberts
Venkataraman Amarnath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of CA3030149A1 publication Critical patent/CA3030149A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CA3030149A 2016-07-07 2017-07-07 Prevention and treatment of atrial fibrillation/flutter with gamma-ketoaldehyde scavengers Pending CA3030149A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662359705P 2016-07-07 2016-07-07
US62/359,705 2016-07-07
PCT/US2017/041211 WO2018009875A1 (en) 2016-07-07 2017-07-07 Prevention and treatment of atrial fibrillation/flutter with gamma-ketoaldehyde scavengers

Publications (1)

Publication Number Publication Date
CA3030149A1 true CA3030149A1 (en) 2018-01-11

Family

ID=60913210

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3030149A Pending CA3030149A1 (en) 2016-07-07 2017-07-07 Prevention and treatment of atrial fibrillation/flutter with gamma-ketoaldehyde scavengers

Country Status (11)

Country Link
US (2) US20190247375A1 (https=)
EP (1) EP3481505B1 (https=)
JP (1) JP7179353B2 (https=)
CN (1) CN110022936A (https=)
AU (1) AU2017293950B2 (https=)
BR (1) BR112019000251A2 (https=)
CA (1) CA3030149A1 (https=)
ES (1) ES3040735T3 (https=)
MX (1) MX393913B (https=)
PL (1) PL3481505T3 (https=)
WO (1) WO2018009875A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620836B1 (en) * 1997-01-22 2003-09-16 Jay Patrick Antiarrhythmic and tranquilizer composition and treatment
US8822542B2 (en) * 2004-10-20 2014-09-02 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
US20070249562A1 (en) 2006-04-25 2007-10-25 Friesen Albert D Treatment of atrial fibrillation
EP2477594A4 (en) * 2009-07-15 2013-03-13 Univ Vanderbilt ISOKETAL CATCHER AND TREATMENT OF DISEASES WITH OXIDATIVE INJURY
US10975033B2 (en) * 2011-07-12 2021-04-13 Vanderbilt University Methods for treating inflammation and hypertension with γ-ketoaldehyde skavengers

Also Published As

Publication number Publication date
EP3481505B1 (en) 2025-09-03
PL3481505T3 (pl) 2026-01-26
MX2019000120A (es) 2019-04-01
BR112019000251A2 (pt) 2019-04-16
AU2017293950B2 (en) 2023-06-15
JP2019520389A (ja) 2019-07-18
WO2018009875A1 (en) 2018-01-11
AU2017293950A1 (en) 2019-01-31
MX393913B (es) 2025-03-24
EP3481505A1 (en) 2019-05-15
JP7179353B2 (ja) 2022-11-29
US20240189291A1 (en) 2024-06-13
EP3481505C0 (en) 2025-09-03
US20190247375A1 (en) 2019-08-15
CN110022936A (zh) 2019-07-16
ES3040735T3 (en) 2025-11-04
EP3481505A4 (en) 2020-02-26

Similar Documents

Publication Publication Date Title
Joshi et al. Drp1/Fis1-mediated mitochondrial fragmentation leads to lysosomal dysfunction in cardiac models of Huntington's disease
Boengler et al. Mitochondria and ageing: role in heart, skeletal muscle and adipose tissue
Errico et al. Decreased levels of D-aspartate and NMDA in the prefrontal cortex and striatum of patients with schizophrenia
Nalivaeva et al. The Alzheimer′ s Amyloid‐Degrading Peptidase, Neprilysin: Can We Control It?
Ferguson et al. Non-sirtuin histone deacetylases in the control of cardiac aging
EP3216447B1 (en) Use of edaravone in preparing drug for preventing and treating cerebral amyloid angiopathy (caa)
Khan et al. Excitotoxicity, oxytosis/ferroptosis, and neurodegeneration: emerging insights into mitochondrial mechanisms
Sukhorukov et al. Mitochondrial disorders in Alzheimer’s disease
Kelliny et al. A new approach to model sporadic Alzheimer’s disease by intracerebroventricular streptozotocin injection in APP/PS1 mice
Palhegyi et al. Biomedical implications of autophagy in macromolecule storage disorders
Varshney et al. Ang (1–7)/Mas receptor-axis activation promotes amyloid beta-induced altered mitochondrial bioenergetics in discrete brain regions of Alzheimer's disease-like rats
Lopez et al. Enhancing endogenous nitric oxide by whole body periodic acceleration elicits neuroprotective effects in dystrophic neurons
WO2016191323A1 (en) Lithium co-crystals for treatment of neuropsychiatric disorders
Palomo et al. The potential role of glycogen synthase kinase 3 inhibitors as amyotrophic lateral sclerosis pharmacological therapy
US20240189291A1 (en) Prevention And Treatment Of Atrial Fibrillation/Flutter With Gamma-Ketoaldehyde Scavengers
Athari et al. AdipoRon improves mitochondrial homeostasis and protects dopaminergic neurons through activation of the AMPK signaling pathway in the 6-OHDA-lesioned rats
HK40003085B (en) Prevention and treatment of atrial fibrillation/flutter with gamma-ketoaldehyde scavengers
HK40003085A (en) Prevention and treatment of atrial fibrillation/flutter with gamma-ketoaldehyde scavengers
Sikazwe et al. Alzheimer’s drug discovery maze: a snap view of the past decade’s diverse pharmacological targets for the disorder
Sakuma et al. Molecular mechanisms controlling skeletal muscle mass
Lee et al. Astrocytic MAOB-GABA axis as a molecular brake on repair following spinal cord injury
Auzmendi et al. Seizures induce hypoxia, and hypoxia induces seizures: A perverse relationship that increases the risk of sudden unexpected death in epilepsy (SUDEP)
Kisvári et al. The effect of acute simvastatin administration on the severity of arrhythmias resulting from ischaemia and reperfusion in the canine: Is there a role for nitric oxide?
US20220087962A1 (en) Compositions and methods for treating age-related diseases or conditions
Govindarajulu Selective PPARγ agonism attenuates pathologies and improves cognitive deficits in Alzheimer's disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220706

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240917

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241218

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250510

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250510

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250627

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250627

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251126